ACAD - ACADIA Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 54.23B
Enterprise Value 33.85B
Trailing P/E N/A
Forward P/E 1-24.40
PEG Ratio (5 yr expected) 1-0.59
Price/Sales (ttm)16.02
Price/Book (mrq)10.88
Enterprise Value/Revenue 314.60
Enterprise Value/EBITDA 6-14.26

Trading Information

Stock Price History

Beta (3Y Monthly) 1.88
52-Week Change 3107.23%
S&P500 52-Week Change 32.12%
52 Week High 330.38
52 Week Low 313.17
50-Day Moving Average 326.98
200-Day Moving Average 325.71

Share Statistics

Avg Vol (3 month) 31.27M
Avg Vol (10 day) 31.1M
Shares Outstanding 5144.49M
Float 104.97M
% Held by Insiders 10.30%
% Held by Institutions 198.72%
Shares Short (Jul 31, 2019) 413.28M
Short Ratio (Jul 31, 2019) 49.85
Short % of Float (Jul 31, 2019) 416.08%
Short % of Shares Outstanding (Jul 31, 2019) 49.19%
Shares Short (prior month Jun 28, 2019) 413.81M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin -101.45%
Operating Margin (ttm)-103.50%

Management Effectiveness

Return on Assets (ttm)-44.03%
Return on Equity (ttm)-81.96%

Income Statement

Revenue (ttm)264.04M
Revenue Per Share (ttm)1.94
Quarterly Revenue Growth (yoy)45.80%
Gross Profit (ttm)18.31M
EBITDA -270.26M
Net Income Avi to Common (ttm)-267.88M
Diluted EPS (ttm)-1.97
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)381.89M
Total Cash Per Share (mrq)2.64
Total Debt (mrq)11.15M
Total Debt/Equity (mrq)2.87
Current Ratio (mrq)6.85
Book Value Per Share (mrq)2.69

Cash Flow Statement

Operating Cash Flow (ttm)-183.93M
Levered Free Cash Flow (ttm)-89.96M